Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics.
GEMM melanoma models
dsRNA nanoplexes
midkine
neolymphangiogenesis
premetastatic niche
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
07 12 2021
07 12 2021
Historique:
revised:
12
10
2021
received:
11
06
2020
accepted:
15
10
2021
pubmed:
12
11
2021
medline:
12
3
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
Long-range communication between tumor cells and the lymphatic vasculature defines competency for metastasis in different cancer types, particularly in melanoma. Nevertheless, the discovery of selective blockers of lymphovascular niches has been compromised by the paucity of experimental systems for whole-body analyses of tumor progression. Here, we exploit immunocompetent and immunodeficient mouse models for live imaging of Vegfr3-driven neolymphangiogenesis, as a versatile platform for drug screening in vivo. Spatiotemporal analyses of autochthonous melanomas and patient-derived xenografts identified double-stranded RNA mimics (dsRNA nanoplexes) as potent inhibitors of neolymphangiogenesis, metastasis, and post-surgical disease relapse. Mechanistically, dsRNA nanoplexes were found to exert a rapid dual action in tumor cells and in their associated lymphatic vasculature, involving the transcriptional repression of the lymphatic drivers Midkine and Vegfr3, respectively. This suppressive function was mediated by a cell-autonomous type I interferon signaling and was not shared by FDA-approved antimelanoma treatments. These results reveal an alternative strategy for targeting the tumor cell-lymphatic crosstalk and underscore the power of Vegfr3-lymphoreporters for pharmacological testing in otherwise aggressive cancers.
Identifiants
pubmed: 34762341
doi: 10.15252/emmm.202012924
pmc: PMC8649872
doi:
Substances chimiques
RNA, Double-Stranded
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12924Informations de copyright
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Med Res Rev. 2018 Sep;38(6):1769-1798
pubmed: 29528507
Nature. 2017 Jun 28;546(7660):676-680
pubmed: 28658220
EMBO Mol Med. 2021 Dec 7;13(12):e12924
pubmed: 34762341
Nature. 2017 Jun 28;546(7660):609-610
pubmed: 28658216
Nat Rev Cancer. 2014 Mar;14(3):159-72
pubmed: 24561443
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
Front Immunol. 2019 Jan 29;10:76
pubmed: 30761143
Annu Rev Immunol. 2019 Apr 26;37:349-375
pubmed: 30673536
J Clin Invest. 2014 Mar;124(3):922-8
pubmed: 24590277
Front Immunol. 2019 Apr 12;10:518
pubmed: 31105685
Nat Med. 2011 Nov 07;17(11):1371-80
pubmed: 22064427
Cancer Cell. 2009 Aug 4;16(2):103-14
pubmed: 19647221
Br J Dermatol. 2021 Dec;185(6):1095-1104
pubmed: 34185875
Sci Signal. 2017 Oct 03;10(499):
pubmed: 28974649
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Cancer Cell. 2019 Jan 14;35(1):46-63.e10
pubmed: 30581152
Adv Drug Deliv Rev. 2017 May 15;114:43-59
pubmed: 28694027
Cancer Cell. 2008 Jun;13(6):554-6
pubmed: 18538738
J Leukoc Biol. 2017 Aug;102(2):277-286
pubmed: 28356350
Clin Exp Metastasis. 2022 Feb;39(1):181-199
pubmed: 33961168
Mod Rheumatol. 2019 Jul;29(4):567-571
pubmed: 30217121
Genesis. 2006 Jan;44(1):34-43
pubmed: 16419042
Nat Med. 2014 Jun;20(6):682-8
pubmed: 24836576
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6
pubmed: 23203888
Nat Med. 2020 Dec;26(12):1865-1877
pubmed: 33077955
Front Oncol. 2021 May 28;11:635488
pubmed: 34123788
Br J Pharmacol. 2014 Jun;171(12):2925-39
pubmed: 24460734
Clin Cancer Res. 2014 Mar 1;20(5):1355-65
pubmed: 24520093
J Clin Invest. 2014 Mar;124(3):878-87
pubmed: 24590272
Curr Opin Oncol. 2020 Mar;32(2):106-113
pubmed: 31876547
Curr Opin Immunol. 2018 Aug;53:7-12
pubmed: 29605736
Oncoimmunology. 2013 Jun 1;2(6):e24677
pubmed: 23894722
Nat Clin Pract Oncol. 2006 Jan;3(1):24-40
pubmed: 16407877
Cancer Cell. 2005 Feb;7(2):121-7
pubmed: 15710325
Autophagy. 2010 Jan;6(1):148-50
pubmed: 19923903
Lymphat Res Biol. 2008;6(3-4):165-72
pubmed: 19093789
Cancers (Basel). 2010 Apr 20;2(2):624-41
pubmed: 24281085
Front Oncol. 2019 Apr 17;9:268
pubmed: 31058079
Am J Cancer Res. 2014 Dec 15;5(1):433-41
pubmed: 25628951
Int J Mol Sci. 2018 Aug 29;19(9):
pubmed: 30158425
Front Pharmacol. 2019 Apr 12;10:377
pubmed: 31031625
Sci Transl Med. 2020 Oct 14;12(565):
pubmed: 33055240
Nat Commun. 2019 Nov 4;10(1):5023
pubmed: 31685822
J Exp Med. 2019 Feb 4;216(2):350-368
pubmed: 30647120
J Clin Invest. 2009 Aug;119(8):2399-411
pubmed: 19620789
Cell Stem Cell. 2017 Nov 2;21(5):665-678.e6
pubmed: 29033353
Pigment Cell Melanoma Res. 2017 Jan;30(6):509-510
pubmed: 28756632
Clin Cancer Res. 2021 May 15;27(10):2678-2697
pubmed: 33414132
Clin Cancer Res. 2011 May 1;17(9):2619-27
pubmed: 21372217
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6223-8
pubmed: 22474390
Pigment Cell Melanoma Res. 2010 Feb;23(1):112-20
pubmed: 20002887
Cancer Cell. 2021 May 10;39(5):610-631
pubmed: 33545064
Nature. 2010 Sep 30;467(7315):596-9
pubmed: 20823850
Eur J Pharmacol. 2019 Nov 5;862:172621
pubmed: 31446019
Nat Rev Immunol. 2004 Jul;4(7):499-511
pubmed: 15229469
Nat Commun. 2016 Nov 18;7:13418
pubmed: 27857118
Pathol Int. 2012 Jul;62(7):445-55
pubmed: 22726064
Oncogene. 2012 Oct 18;31(42):4499-508
pubmed: 22179834
J Immunother Cancer. 2019 May 2;7(1):116
pubmed: 31046839
Science. 1994 Jun 24;264(5167):1918-21
pubmed: 8009221
Dev Cell. 2017 Aug 7;42(3):205-207
pubmed: 28787586
Int J Oncol. 2012 Oct;41(4):1455-63
pubmed: 22797548
Ann Oncol. 2015 Jan;26(1):33-39
pubmed: 24907634
Cancer Immunol Res. 2014 Aug;2(8):720-4
pubmed: 24801836
Cancer Res. 2010 Jul 1;70(13):5518-27
pubmed: 20551065
Cell Stem Cell. 2017 Nov 2;21(5):559-561
pubmed: 29100006
Development. 2002 Jul;129(14):3513-22
pubmed: 12091320
Cell Stem Cell. 2017 Nov 2;21(5):679-693.e6
pubmed: 29033351
Nat Genet. 2009 May;41(5):544-52
pubmed: 19282848